Codexis

ADARx Pharmaceuticals Expands Leadership Team

Retrieved on: 
Martedì, Gennaio 25, 2022
Biotechnology, Pharmaceutical, Genetics, Health, University, Indiana University School of Medicine, Therapy, VP, Doctor of Philosophy, RNA, Kelley School of Business, Codexis, CMC, Peripheral nervous system, MBA, Organic chemistry, Business, Oligonucleotide, Management, CGMP, Indiana University

ADARx Pharmaceuticals, Inc. , a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Christopher D. Claeboe, Ph.D., MBA as VP, CMC and Manufacturing.

Key Points: 
  • ADARx Pharmaceuticals, Inc. , a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Christopher D. Claeboe, Ph.D., MBA as VP, CMC and Manufacturing.
  • I am excited to welcome Chris to the ADARx team at this important time in our company, said Dr. Zhen Li, President and Chief Executive officer of ADARx.
  • Dr. Claeboe brings to ADARx extensive experience in CGMP drug substance and drug product manufacturing through various stages of clinical development to commercialization.
  • ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics.

Asher Bio Expands Leadership Team with Three Key Appointments

Retrieved on: 
Lunedì, Gennaio 24, 2022
Biotechnology, Pharmaceutical, Health, Third Rock Ventures, Doctor of Philosophy, New Paltz, New York, Research, Patient, Regulatory affairs, Guidant, University, LinkedIn, Codexis, Biotechnology, Tufts University, Forty-seven rōnin, Regulation of tobacco by the U.S. Food and Drug Administration, Market for corporate control, Molecular biology, Wharton School of the University of Pennsylvania, Gilead Sciences, Autoimmunity, Amgen, Leadership, Infection, CPA, Industry, Varian, Inc., Program, Therapy, Davis, 5, University of Washington Department of Global Health, Certified Public Accountant, Toxicity, Cancer, Food, State university system, Outcomes research, FDA, LLC, Wendell Pritchett, Imperial College London, Head, Pharmaceutical industry, Vaccine, Genentech, Biology, Biochemistry, Immunology

We are delighted to welcome Don, Jamie and Florence to Asher Bio, said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio.

Key Points: 
  • We are delighted to welcome Don, Jamie and Florence to Asher Bio, said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio.
  • Dr. OSullivan joins Asher Bio from Roche and Genentech, where he served most recently as Vice President, Global Head of Oncology Partnering, with responsibility for all oncology pipeline business development activities.
  • Prior to Asher Bio, Dr. Cross founded and served as the principal regulatory consultant of Cross BioStrategies, LLC, where he assisted companies with product development strategies, regulatory filings, and regulatory leadership.
  • Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco.

Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria

Retrieved on: 
Lunedì, Gennaio 24, 2022
Ageing, Synthetic biology, Cystathionine, HCU, Stroke, Person, Stomach, Private Securities Litigation Reform Act, Pyridoxine, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intellectual, Enzyme, Homocystinuria, Homocysteine, NASDAQ, CEO, Learning, ODD, GLOBE, Human services, International Congress on Tuberculosis, GARD, Department, Methionine, Health, U.S. Securities and Exchange Commission, Urine, United States Department of Health and Human Services, MTHFR, CBS, Marketing, Program, Cardiovascular disease, Company, Betaine, Diagnosis, Disorder, RPD, Food, Therapy, Blood, FDA, Genetic, Osteoporosis, Security (finance), Annual report, Pharmaceutical industry, Dietary supplement, Metabolism, Codexis

The FDA also granted the company rare pediatric disease (RPD) designation for CDX-6512.

Key Points: 
  • The FDA also granted the company rare pediatric disease (RPD) designation for CDX-6512.
  • CDX-6512 is currently in pre-IND development and is the most advanced wholly owned program in the Companys biotherapeutics pipeline.
  • The orphan drug and rare pediatric disease designations for CDX-6512 further build upon the momentum our engineered enzymes have generated as potential first-in-class oral therapeutics for inborn errors of metabolism, said John Nicols, President and CEO of Codexis.
  • These designations represent an important step forward in the development of CDX-6512 as a potential treatment of homocystinuria and we look forward to continuing its advancement toward the clinic.

Acepodia Announces Expansion of Board of Directors and Scientific Advisory Board

Retrieved on: 
Giovedì, Gennaio 6, 2022
Therapy, Oncology, Growth, Founder, Director, Research, Patient, Senior advisor, Stanford University School of Medicine, Duke University School of Medicine, History, Hematological Cancer Research Investment and Education Act, Cancer, Dendreon, Juno Therapeutics, Central Washington University, Twitter, Neoplasm, Smith, Golden Gate University, Willamette University, ACC, Genentech, Coronavirus Scientific Advisory Board (Turkey), Regulatory affairs, CEO, Regulation, MBA, Gaps, LinkedIn, ACE, Senior, Population, Hematology, Bill & Melinda Gates Foundation, Board, GLOBE, Biology, Codexis, Amgen, NK, Technology, Haematopoietic system, Board of directors, Associate, Industry, Leadership, Biotechnology, IBM, Pharmaceutical industry, Management, Medical imaging, Economics, Medicine

ALAMEDA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care, today announced it has appointed David V. Smith to its Board of Directors and Elizabeth Smith and Richard Lopez, M.D., to its Scientific Advisory Board.

Key Points: 
  • I am honored to join such a strong board of directors and bring more than 30 years of financial and operational management experience across private and public companies to support the long-term growth and success of Acepodia, Mr. Smith said.
  • He is also Associate Professor of Medicine at Duke University School of Medicine where he engages in extensive research in hematology.
  • Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care.
  • For more information, visit https://www.acepodia.com and follow Acepodia on Twitter and LinkedIn .

Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference

Retrieved on: 
Mercoledì, Gennaio 5, 2022
GLOBE, Codexis, Webcast, Health, Therapy, Synthetic biology, Food, Investor relations, Conference, Enzyme, Fine chemical

REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

Key Points: 
  • REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.
  • A webcast of the fireside chat will be available on-demand beginning Monday, January 10, 2022 at 7:00 a.m.
  • Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver platform to discover and develop novel, high performance enzymes and novel biotherapeutics.
  • Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.

NovoNutrients Hires Four Technology Leaders to Make Protein From CO2

Retrieved on: 
Martedì, Gennaio 4, 2022
Heidelberg University, CTO, Chemical engineering, Safety, University, Biology, Doctor of Philosophy, Kedar, UC, Indian Institute of Technology (BHU) Varanasi, DNA, Molecular biology, Food, Institute, Institute of Chemical Technology, Hydrogen, Microbiology, Publication, Bhupendra, Siluria Technologies, Health, MBA, Greenhouse, Bacteria, Yeast, DuPont Central Research, University of California, Berkeley, Codexis, Technical, Biochemical engineering, DeVry University, BS, VP, Stanford University, Carbon, CO2, Fine chemical, Management, Calysta, Technology, Amyris, Engineering, Fermentation, Research, Satish

NovoNutrients' CEO, David Tze, said, "we are now fully positioned to build on our technology foundation and become a leading protein ingredients company, with the addition of these four industry experts.

Key Points: 
  • NovoNutrients' CEO, David Tze, said, "we are now fully positioned to build on our technology foundation and become a leading protein ingredients company, with the addition of these four industry experts.
  • Satish Lakhapatri, VP Engineering, joins NovoNutrients after nearly four years with industrial biotech company Calysta, where he was the Director of Engineering.
  • About NovoNutrients https://www.novonutrients.com NovoNutrients is the food and feed from CO2 bio company that cleanly transforms carbon dioxide emissions into microbial alternative protein ingredients.
  • Also using other byproduct streams and hydrogen, this low-cost, highly-scalable technology addresses the growing demand of rising global standards of living.

Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing

Retrieved on: 
Mercoledì, Dicembre 15, 2021
Electric Bond and Share Company v. Securities and Exchange Commission, RNA, PCR, Reverse transcriptase, Private Securities Litigation Reform Act, RT, A-DNA, COVID-19, Annual report, NASDAQ, SEC, Temperature, CEO, Therapy, Security (finance), DNA, Enzyme, Synthetic biology, GLOBE, Tonian, Food, Orthornavirae, Health, Real-time, Fine chemical, Vaccine, Codexis

This enzyme is specifically engineered and optimized for enhanced thermostability and robustness to address known challenges in handling clinical samples.

Key Points: 
  • This enzyme is specifically engineered and optimized for enhanced thermostability and robustness to address known challenges in handling clinical samples.
  • A reverse transcriptase is an essential enzyme for the naturally occurring process of reverse transcription, whereby an RNA sequence is converted into complementary DNA (cDNA).
  • In life science applications, this reverse transcriptase is critical for the detection of RNA viruses.
  • These include, without limitation, statements about the thermostability, robustness and faster turnaround time of Codex HiTemp Reverse Transcriptase and the potential use of Codex HiTemp Reverse Transcriptase for one-step RT-qPCR assays.

ParentSquare Appoints Derick Sutton as Chief Financial Officer

Retrieved on: 
Mercoledì, Dicembre 1, 2021
Chapel Hill, CEO, School, Labour law, Software as a service, San Francisco Bay Area, MBA, Human, IPO, Codexis, SCI, University, Solution, University of California, Riverside, K-12, CFO, BC, University of North Carolina at Greensboro, CA, Small business, Growth, Intuit, Management

SANTA BARBARA, Calif., Dec. 1, 2021 /PRNewswire-PRWeb/ -- ParentSquare Inc. , provider of the premier unified school-to-home engagement platform for K-12, announced that Derick Sutton is joining the company as its Chief Financial Officer (CFO).

Key Points: 
  • SANTA BARBARA, Calif., Dec. 1, 2021 /PRNewswire-PRWeb/ -- ParentSquare Inc. , provider of the premier unified school-to-home engagement platform for K-12, announced that Derick Sutton is joining the company as its Chief Financial Officer (CFO).
  • Sutton has extensive experience as a financial leader at high-growth technology companies.
  • Sutton also held several executive roles at the financial software and SaaS company Intuit.
  • "We're excited to welcome Derick to our team," said Sohit Wadhwa, CEO of ParentSquare.

Codexis to Participate in Upcoming Virtual Healthcare Conferences

Retrieved on: 
Venerdì, Novembre 19, 2021
Conference, Evercore, Health, Synthetic biology, Codexis, Therapy, Piper Sandler Companies, GLOBE, Food, Enzyme, Investor relations, Animal, Fine chemical

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, todayannounced that management will participate in three upcoming virtual investment conferences.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, todayannounced that management will participate in three upcoming virtual investment conferences.
  • The Piper Sandler 33rd Annual Virtual Healthcare Conference on-demand fireside chat available beginning November 22, 2021 at 10:00 a.m.
  • ET
    The Evercore ISI 4th Annual HealthCONx Virtual Conference fireside chat on November 30, 2021 at 4:45 p.m.
  • Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.

Codexis to Participate in Upcoming Virtual Healthcare Conferences

Retrieved on: 
Martedì, Novembre 9, 2021
Codexis, Health, Investor relations, Conference, Synthetic biology, GLOBE, Food, Therapy, Jefferies, Enzyme, Stifel, Fine chemical, Animal

REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, todayannounced that management will participate in three upcoming virtual investment conferences.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, todayannounced that management will participate in three upcoming virtual investment conferences.
  • The 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021, management will attend and host 1x1 investor meetings
    The Stifel 2021 Virtual Healthcare Conference November 17, 2021 at 2:40 p.m.
  • ET, fireside chat
    The Jefferies London Healthcare Conference November 18, 2021 at 3:00 a.m.
  • Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.